Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial.

Zhenyu WenJunxiao WangBo TuYane LiuYuqing YangLi HouXiang YangXiaoyan LiuHui Xie

Published in: Cancer medicine (2023)

Combining RFA with anti-PD-1 showed improved RFS and was deemed safe for patients with recurrent HCC who had previously undergone RFA treatment alone.

Keyphrases

radiofrequency ablation
study protocol
open label
randomized controlled trial
clinical trial
double blind